ArticleFrontiers in immunology2026
PANoptosis-related genes in rheumatoid arthritis synovial tissue: screening, validation, and functional implications.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic Properties and Underlying Mechanisms of Traditional Chinese Medicine in Managing Rheumatoid Arthritis: An Integrative Review of Clinical and Molecular Findings.Phytotherapy research : PTR · 2026Review
- Investigation of complex miRNA-mRNA interaction networks during JAK inhibitor therapy in rheumatoid arthritis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To screen and validate the expression of key PANoptosis-related genes in the synovial tissue of rheumatoid arthritis (RA) through bioinformatics approaches and Methods: Based on multiple genomic datasets from the GEO database, differentially expressed genes (DEGs) were screened using tools such as the limma package. The STRING database and Cytoscape 3.7.0 were employed to construct a Protein-Protein Interaction (PPI) network, followed by Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Meanwhile, the CIBERSORT algorithm was used to perform immune infiltration analysis on the merged dataset to evaluate the proportional differences of 22 immune cell subsets. Classic Results: Thirteen key DEGs involved in the PANoptosis pathway were identified in RA. GO and KEGG enrichment analyses showed that these genes were mainly involved in the NOD-like receptor signaling pathway and apoptosis signaling pathway. Immune infiltration analysis revealed significant differences in the immune microenvironment between RA patients and healthy controls: the RA group showed significant enrichment of pro-inflammatory immune cell subsets, while the control group was enriched with cells with inhibitory or homeostasis-maintaining functions. Compared with normal rats, the synovial tissue of AIA rats exhibited obvious abnormal hyperplasia. Western Blot (WB) results indicated that, compared with the control group, the expression levels of IL-18, NLRP3, GBP1, TNFSF10, Caspase-1, and Bcl-2 proteins in RAFLSs and AIA rat synovial tissue were significantly increased, while the expression levels of Bax and Caspase-3 were significantly decreased. Conclusion: During the pathogenesis of RA, the key PANoptosis markers (IL-18, NLRP3, GBP1, TNFSF10, Bax, Bcl-2, Caspase-1, and Caspase-3) are involved in invasive synovial hyperplasia. The characteristic immune cell imbalance in RA provides conditions for these key PANoptosis markers to regulate immune cell functions, and it is an important basis for the pathological changes of joint synovial hyperplasia in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.